Roscovitine differentially affects CaV2 and Kv channels by binding to the open state

Neuropharmacology

Volumn 52, Issue 3, 2007, Pages 883-894

  Buraei, Zafir ^a,b   Schofield, Geoffrey ^a   Elmslie, Keith S ^a,c  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Bullfrog sympathetic neurons; CaV cell lines; CaV2 enhancement; Kv inhibition; Open channel; Whole cell patch clamp

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM CHANNEL R TYPE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; POTASSIUM CHANNEL; ROSCOVITINE; SODIUM CHANNEL;

ANIMAL CELL; ARTICLE; BULLFROG; CELL DIVISION; CHANNEL GATING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; SYMPATHETIC NERVE CELL;

CALCIUM CHANNELS, L-TYPE; CAVEOLIN 2; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRIC STIMULATION; HUMANS; ION CHANNEL GATING; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; PROTEIN KINASE INHIBITORS; PURINES; TRANSFECTION;

EID: 33846903576     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.10.006     Document Type: Article

References (54)

1. Bean B.P. Two kinds of calcium channels in canine atrial cells. Differences in kinetics, selectivity, and pharmacology. J. Gen. Physiol. 86 (1985) 1-30
2. Boland L.M., Morrill J.A., and Bean B.P. omega-Conotoxin block of N-type calcium channels in frog and rat sympathetic neurons. J. Neurosci. 14 (1994) 5011-5027
3. Buraei Z., Anghelescu M., and Elmslie K.S. Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor Roscovitine. Biophys. J. 89 (2005) 1681-1691
4. Cho S., and Meriney S.D. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur. J. Neurosci. 23 (2006) 3200-3208
5. Cloues R.K., and Sather W.A. After hyperpolarization regulates firing rate in neurons of the suprachiasmatic nucleus. J. Neurosci. 23 (2003) 1593-1604
6. Colecraft H.M., Brody D.L., and Yue D.T. G-protein inhibition of N- and P/Q-type calcium channels: distinctive elementary mechanisms and their functional impact. J. Neurosci. 21 (2001) 1137-1147
7. Constanti A., and Brown D.A. M-currents in voltage-clamped mammalian sympathetic neurones. Neurosci. Lett. 24 (1981) 289-294
8. Conti M. Targeting K+ channels for cancer therapy. J. Exp. Ther. Oncol. 4 (2004) 161-166
9. Darios F., Muriel M.P., Khondiker M.E., Brice A., and Ruberg M. Neurotoxic calcium transfer from endoplasmic reticulum to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau. J. Neurosci. 25 (2005) 4159-4168
10. De Azevedo W., Leclerc S., Meijer L., Havlicek L., Strnad M., and Kim S. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243 (1997) 518-526
11. de la Motte S., and Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int. J. Clin. Pharmacol. Ther. 42 (2004) 232-239
12. Elmslie K.S. Calcium channel blockers in the treatment of disease. J. Neurosci. Res. 75 (2004) 733-741
13. Elmslie K.S., Zhou W., and Jones S.W. LHRH and GTP-gamma-S modify calcium current activation in bullfrog sympathetic neurons. Neuron 5 (1990) 75-80
14. Elmslie K.S., Kammermeier P.J., and Jones S.W. Calcium current modulation in frog sympathetic neurones: L-current is relatively insensitive to neurotransmitters. J. Physiol. 456 (1992) 107-123
15. Ertel E.A., Campbell K.P., Harpold M.M., Hofmann F., Mori Y., Perez-Reyes E., Schwartz A., Snutch T.P., Tanabe T., Birnbaumer L., Tsien R.W., and Catterall W.A. Nomenclature of voltage-gated calcium channels. Neuron 25 (2000) 533-535
16. Fraser S.P., Grimes J.A., and Djamgoz M.B. Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate 44 (2000) 61-76
17. Fujii S., Kameyama K., Hosono M., Hayashi Y., and Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 280 (1997) 1184-1191
18. Guzi T. CYC-202 Cyclacel. Curr. Opin. Investig. Drugs 5 (2004) 1311-1318
19. Havlicek L., Hanus J., Vesely J., Leclerc S., Meijer L., Shaw G., and Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40 (1997) 408-412
20. Hillyard D.R., Monje V.D., Mintz I.M., Bean B.P., Nadasdi L., Ramachandran J., Miljanich G., Azimi-Zoonooz A., McIntosh J.M., Cruz L.J., Imperial J.S., and Olivera B.M. A new Conus peptide ligand for mammalian presynaptic Ca2+ channels. Neuron 9 (1992) 69-77
21. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., and Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1 (1999) 60-67
22. Iseki H., Ko T.C., Xue X.Y., Seapan A., Hellmich M.R., and Townsend Jr. C.M. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery 122 (1997) 187-194 (discussion 194-195)
23. Iseki H., Ko T.C., Xue X.Y., Seapan A., and Townsend Jr. C.M. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. J. Gastrointest. Surg. 2 (1998) 36-43
24. Jones S.W. Sodium currents in dissociated bull-frog sympathetic neurones. J. Physiol. 389 (1987) 605-627
25. Jones S.W., and Marks T.N. Calcium currents in bullfrog sympathetic neurons. I. Activation kinetics and pharmacology. J. Gen. Physiol. 94 (1989) 151-167
26. Klemic K.G., Durand D.M., and Jones S.W. Activation kinetics of the delayed rectifier potassium current of bullfrog sympathetic neurons. J. Neurophysiol. 79 (1998) 2345-2357
27. Kuffler S.W., and Sejnowski T.J. Peptidergic and muscarinic excitation at amphibian sympathetic synapses. J. Physiol. 341 (1983) 257-278
28. Lee H.R., Chang T.H., Tebalt III M.J., Senderowicz A.M., and Szabo E. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. Int. J. Oncol. 15 (1999) 161-166
29. Magistretti J., Brevi S., and de Curtis M. A blocker-resistant, fast-decaying, intermediate-threshold calcium current in palaeocortical pyramidal neurons. Eur. J. Neurosci. 12 (2000) 2376-2386
30. Magistretti J., Brevi S., and de Curtis M. Ni2+ slows the activation kinetics of high-voltage-activated Ca2+ currents in cortical neurons: evidence for a mechanism of action independent of channel-pore block. J. Membr. Biol. 179 (2001) 243-262
31. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., MacKenzie M., Melville J., Stewart K., Wang S., Zhelev N., Zheleva D., and Lane D.P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102 (2002) 463-468
32. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 6 (1996) 393-397
33. Meijer L., Borgne A., Mulner O., Chong J., Blow J., Inagaki N., Inagaki M., Delcros J., and Moulinoux J. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243 (1997) 527-536
34. Mgbonyebi O.P., Russo J., and Russo I.H. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells. Anticancer Res. 18 (1998) 751-755
35. Mihara M., Shintani S., Kiyota A., Matsumura T., and Wong D.T. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int. J. Oncol. 21 (2002) 95-101
36. Mould J., Yasuda T., Schroeder C.I., Beedle A.M., Doering C.J., Zamponi G.W., Adams D.J., and Lewis R.J. The alpha2delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Cav2.2) calcium channels. J. Biol. Chem. 279 (2004) 34705-34714
37. Nilius B., Hess P., Lansman J.B., and Tsien R.W. A novel type of cardiac calcium channel in ventricular cells. Nature 316 (1985) 443-446
38. Nowycky M.C., Fox A.P., and Tsien R.W. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 316 (1985) 440-443
39. Randall A., and Tsien R.W. Pharmacological dissection of multiple types of Ca2+ channel currents in rat cerebellar granule neurons. J. Neurosci. 15 (1995) 2995-3012
40. Raynaud F.I., Whittaker S.R., Fischer P.M., McClue S., Walton M.I., Barrie S.E., Garrett M.D., Rogers P., Clarke S.J., Kelland L.R., Valenti M., Brunton L., Eccles S., Lane D.P., and Workman P. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin. Cancer Res. 11 (2005) 4875-4887
41. Schofield G.G., and Ricci A. Electrophysiological characterization of C-terminal Kv4 channel fusion proteins. Pflugers Arch. 450 (2005) 245-254
42. Senderowicz A.M. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. 2 (2003) S84-S95
43. Splawski I., Timothy K.W., Decher N., Kumar P., Sachse F.B., Beggs A.H., Sanguinetti M.C., and Keating M.T. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc. Natl. Acad. Sci. U.S.A 102 (2005) 8089-8096 (discussion 8086-8088)
44. Sturek M., and Hermsmeyer K. Calcium and sodium channels in spontaneously contracting vascular muscle cells. Science 233 (1986) 475-478
45. Tomizawa K., Ohta J., Matsushita M., Moriwaki A., Li S.-T., Takei K., and Matsui H. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J. Neurosci. 22 (2002) 2590-2597
46. Tottene A., Moretti A., and Pietrobon D. Functional diversity of P-type and R-type calcium channels in rat cerebellar neurons. J. Neurosci. 16 (1996) 6353-6363
47. Triggle D.J. Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev. Technol. 1 (2003) 719-733
48. Vita M., Abdel-Rehim M., Nilsson C., Hassan Z., Skansen P., Wan H., Meurling L., and Hassan M. Stability, pKa and plasma protein binding of roscovitine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 821 (2005) 75-80
49. Vitali L., Yakisich J.S., Vita M.F., Fernandez A., Settembrini L., Siden A., Cruz M., Carminatti H., Casas O., and Idoyaga Vargas V. Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Lett. 180 (2002) 7-12
50. Wilson S.M., Toth P.T., Oh S.B., Gillard S.E., Volsen S., Ren D., Philipson L.H., Lee E.C., Fletcher C.F., Tessarollo L., Copeland N.G., Jenkins N.A., and Miller R.J. The status of voltage-dependent calcium channels in alpha 1E knock-out mice. J. Neurosci. 20 (2000) 8566-8571
51. Wu L.G., Westenbroek R.E., Borst J.G., Catterall W.A., and Sakmann B. Calcium channel types with distinct presynaptic localization couple differentially to transmitter release in single calyx-type synapses. J. Neurosci. 19 (1999) 726-736
52. Xu W., and Lipscombe D. Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J. Neurosci. 21 (2001) 5944-5951
53. Yan Z., Chi P., Bibb J.A., Ryan T.A., and Greengard P. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J. Physiol. (Lond.) 540 (2002) 761-770
54. Yasuda R., Sabatini B.L., and Svoboda K. Plasticity of calcium channels in dendritic spines. Nat. Neurosci. 6 (2003) 948-955